Immune to Cancer: The CRI Blog
-
Cancer Research Institute Raises $1.2 Million at Annual Through the Kitchen
On Sunday, May 16, 2016, the Cancer Research Institute (CRI) held its 34th annual “Through the Kitchen”…
-
FDA Approves Nivolumab (Opdivo) for Advanced Hodgkin Lymphoma Patients
Nivolumab becomes first checkpoint immunotherapy approved for lymphoma.
-
Questions About Cancer Immunotherapy? Ask a Scientist!
We’re excited to present our newest educational initiative for patients—the Ask a Scientist video series.
-
#AACR16 Update: Vice President Biden and the National Cancer Moonshot Initiative
VP Biden addresses AACR16 seeking suggestions and solutions.
-
#AACR16 Update: The Promise of Synthetic Biology and CAR T Cell Technologies
Genetically engineered cells can be customized to target cancer.
-
#AACR16 Update: New Hope for Patients with Rare Skin Cancer, Head & Neck Cancer
Anti-PD-1 blockade and two other types of immunotherapy effective in treating multiple tumor types.
-
#AACR16 Update: The Cancer Research Institute’s Impact on Immunotherapy
Since our founding in 1953, the Cancer Research Institute has pioneered the field of cancer immunology, and… -
#AACR16 Update: How Immune Infiltration Predicts Survival in Cancer Patients
The Immunoscore is the strongest prognostic marker in colorectal cancer.
-
#AACR16 Update: Combination Therapies to Improve Anti-cancer Immune Responses
Complementary treatments can help overcome resistance to immunotherapy.
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.